与CDK4/6抑制剂相关的状角膜病变:一个病例报告
Lian Shu1, Xinhan Cui1, Yan Wang1
1Department of Ophthalmology & Visual Science, Eye & ENT Hospital, Shanghai Medical College, Fudan University, No.83 Fenyang Road, Shanghai, 200031, China.
BMC ophthalmology
|April 14, 2025
概括
用于乳腺癌的环素依赖性激酶 (CDK) 4/6 抑制剂可能会导致罕见的状角质病. 这一案例突出了角膜发现,并强调了对这些新型抗癌药物患者的眼部副作用的监测.
科学领域:
- 眼科医生 眼科 眼科
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 循环素依赖激酶 (CDK) 4/6 抑制剂是新型抗癌药物的一类.
- 这些抑制剂通过阻止细胞循环和阻止癌症进展来起作用.
- 这项研究侧重于与乳腺癌CDK4/6抑制剂治疗相关的状角膜病变的罕见实例.
研究的目的:
- 为了呈现一种罕见的状角质病症病例.
- 描述眼睛的特征和角膜共聚焦显微镜的发现.
- 为了增强对药物诱导的状角质病变机制的理解.
主要方法:
- 一个60岁的女性患者的病例报告,她有转移性乳腺癌的病史.
- 患者呈现了一年的眼睛刺激病史.
- 诊断包括裂纹灯检查,前段光学连贯性断层扫描 (AS-OCT) 和角膜共聚焦显微镜.
- 治疗包括提雷姆西克利布 (一种CDK4/6抑制剂) 和富尔韦斯特兰特.
主要成果:
- 患者被诊断出患有状角质病.
- 角膜共聚焦显微镜揭示了特征性的发现.
- 眼部症状通过人工滑眼滴略有改善.
结论:
- 这个案例说明了CDK4/6抑制剂相关的状角质病变的眼部表现.
- 介绍了角膜共聚焦显微镜的新发现.
- 这项研究提高了人们对与新型抗癌药物相关的潜在眼部副作用的认识.
相关概念视频
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


